Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | — | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
Meningitis | D008581 | EFO_0000584 | G03 | 1 | — | — | — | — | 1 |
Cryptococcal meningitis | D016919 | EFO_0007228 | B45.1 | 1 | — | — | — | — | 1 |
Drug common name | LABRADIMIL |
INN | labradimil |
Description | Labradimil is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target B2 bradykinin receptor. |
Classification | Protein |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc(C[C@@H](CN[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](Cc2cccs2)NC(=O)CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CCCNC(=N)N)cc1 |
PDB | — |
CAS-ID | 159768-75-9 |
RxCUI | — |
ChEMBL ID | CHEMBL2105864 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 2MK663C346 (ChemIDplus, GSRS) |